Journal ArticleDOI
Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma
Rao Prabhala,Mariateresa Fulciniti,Dheeraj Pelluru,Puru Nanjappa,Christine Pai,Saem Lee,Nithya Prabhala,Weihua Song,Constantine S. Mitsiades,Konstantinos Lefkimmiatis,Yu-Tzu Tai,Irene M. Ghobrial,Paul G. Richardson,John F. Daley,Kenneth C. Anderson,Seth Ettenberg,Franco Di Padova,Nikhil C. Munshi +17 more
TLDR
In the SCIDhu model of human myeloma where MM cells grow within the human microenvironment in the mice, administration of AIN-457 weekly for 4 weeks after the first detection of tumor in mice led to a significant inhibition of tumor growth as measured by human sIL-6 receptor compared to control mice.About:
This article is published in Blood.The article was published on 2010-11-19. It has received 2 citations till now. The article focuses on the topics: In vivo & Cell growth.read more
Citations
More filters
Journal ArticleDOI
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma
TL;DR: An overview of various monoclonal antibodies directly targeting myeloma tumor cells or indirectly via effects on the bone marrow microenvironment and the combination of these mAbs with IMiDs or bortezomib is given.
Journal ArticleDOI
Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation
Marco Tucci,Stefania Stucci,Annalisa Savonarola,Sabino Ciavarella,Paola Cafforio,Franco Dammacco,Franco Silvestris +6 more
TL;DR: High IL17A expression in the marrow plasma of MM patients in parallel with its deposits within the stromal matrix suggests that their bone resorption activity is also regulated, at least in vitro, by IL17RA.